Board of Directors
Roger I. Gale, M.E., Chairman of the Board
Mr. Gale is Chief Executive Officer and Chairman of the Board of Sedia Biosciences. As a co-founder, he has been with the Company since its inception in 2009 and served as Chairman since then. Mr. Gale also served as an Independent Director of Mechel OAO, (NYSE: MTL) from 2004 to June 2014. Previously, Mr. Gale served as Chairman of the Board of Calypte Biomedical Sciences from November 2004 until December 2008 and CEO and President until May 2008. He has also served as Executive Chairman of Wavecrest Group Enterprises Limited, a United Kingdom-based communications service provider (2001-2006) and Chairman and co-founder of End2End Wireless Limited, a UK wireless access services provider (1999-2001). He was also CEO of the Moscow–based, OPIC-guaranteed, AIG-Brunswick Millennium Fund (1995-1999) and held senior positions with the Asian Development Bank (ADB, Manila) and the International Finance Corporation (IFC, World Bank, Washington, D.C.) Mr. Gale lectured in economics at the University of New England (Australia) and Lincoln College (New Zealand). Mr. Gale holds a Master of Economics, University of New England, Australia.
Ronald W. Mink, Ph.D., Member of the Board
Dr. Mink has served as President and Chief Science Officer of Sedia Biosciences since 2009 and is also a co-founder. Dr. Mink has been on the board since its founding. Previously, Dr. Mink served as Chief Science Officer (CSO) of Calypte Biosciences from June 2005 until December 2008 and as Director of R&D at Calypte from 2003 until 2005. He also served as a full time consultant for Calypte from 2001 to 2003. At Calypte, he introduced rapid point of care diagnostic testing technology to the company, established the oral fluid diagnostic product line, oversaw development of the BED HIV-1 Incidence EIA and expanded the company’s Aware™ line of HIV products, and launched the creation of its new Life Sciences Division. Prior to Calypte, he was Director of R&D at OraSure Technologies, Inc. (NASDAQ: OSUR). Dr. Mink holds several patents for oral fluid diagnostic tests, including the OraQuick® HIV rapid test, the first U.S. FDA approved rapid oral fluid HIV test. and other tests for oral disease pathogens. He has prior experience successfully developing and commercializing rapid assays in such companies as Eli Lilly and Co.’s diagnostic group and Carter Wallace, culminating in the commercialization of several products including First Response® One Step Pregnancy Test, First Response® 3 Minute Ovulation Test, CARDS QS® hCG, CARDS OS® Strep B and other point-of-care and OTC tests. Dr. Mink received his Ph.D. in Microbiology from the University of Illinois and B.S. and M.S. from Ohio State University.
Lynnor Stevenson, Ph.D., Member of the Board
Dr. Stevenson has served as a board member of Sedia since 2010 and is Chief Executive Officer of Design Medix of Portland Oregon. DesignMedix is a pharmaceutical company focused on globally-important infectious diseases including malaria, bacterial diarrhea and other diseases. Dr. Stevenson is a successful entrepreneur with thirty years experience in the formation and growth of bioscience companies. She has most recently been a Managing Partner of Alta Biomedical Group, a consulting firm that handles projects in the commercialization of innovative technology. She has been a member of the early-stage management teams for ten start-up companies, six of which are now public. She was founding CEO for 5 years and a director for 18 years of Heska Corporation, an animal health company that develops drugs, vaccines and diagnostics. She was a member of the early-stage teams for Creative BioMolecules (now Curis), AP Pharma, Agen and Univax (now Nabi). In addition to business and R&D experience relating to drugs, vaccines and diagnostics, she has experience in drug development at several companies including the submission of several IND (Investigational New Drug) applications to the FDA. She received B.Sc.Hon. and B.Ed. degrees from Melbourne University and a Ph.D in Biochemistry from Monash University, Australia.